One phase II trial (NCT03161379) of neoadjuvant nivolumab with GVAX (GM-CSF secreting allogeneic pancreatic tumor cell vaccine) and cyclophosphamide has completed accrual and is in the follow-up period. This evidence concerns the gene CSF2 and pancreatic neoplasm.